ECOLOGICAL &CLINICAL SIG OF DEFECTIVE ESTROGEN RECEPTOR FROM HUMAN BREAST TUMOR

$0P41FY2002RRNIH

University Of California San Francisco, San Francisco CA

Investigators

Linked publications & trials

Paper 34844857 Paper 33028660 Paper 31204099 Paper 29907569 Paper 29654160 Paper 29487104 Paper 28778876 Paper 28578850 Paper 27649525 Paper 27251789 Paper 27128997 Paper 27127798 Paper 27006500 Paper 26961658 Paper 26729708 Paper 26006010 Paper 25166742 Paper 25153195 Paper 24974296 Paper 24841206 Paper 24529992 Paper 24510890 Paper 24488826 Paper 24425750 Paper 24402695 Paper 24362263 Paper 24019147 Paper 23953109 Paper 23747011 Paper 23664614 Paper 23639431 Paper 23629657 Paper 23480256 Paper 23475669 Paper 23410521 Paper 23362256 Paper 23345524 Paper 23333304 Paper 23300442 Paper 23264352 Paper 23239825 Paper 23237383 Paper 23226976 Paper 23201124 Paper 23190395 Paper 23144648 Paper 23115187 Paper 23059470 Paper 23023596 Paper 22949553 Paper 22918439 Paper 22878499 Paper 22841314 Paper 22821268 Paper 22817900 Paper 22802652 Paper 22751498 Paper 22577016 Paper 22576084 Paper 22571327 Paper 22561460 Paper 22499768 Paper 22466421 Paper 22445341 Paper 22444582 Paper 22444387 Paper 22393263 Paper 22351294 Paper 22328712 Paper 22322595 Paper 22308409 Paper 22267324 Paper 22258260 Paper 22211580 Paper 22190037 Paper 22190034 Paper 22176556 Paper 22137581 Paper 22117532 Paper 22094702 Paper 22027198 Paper 21980548 Paper 21952759 Paper 21937731 Paper 21855796 Paper 21840988 Paper 21798377 Paper 21777475 Paper 21771977 Paper 21718766 Paper 21704604 Paper 21695130 Paper 21627121 Paper 21606357 Paper 21602791 Paper 21526149 Paper 21517887 Paper 21515758 Paper 21490164 Paper 21477079

Abstract

Loss of the DNA-binding function of estrogen receptor (ER) has been observed in 40% of ER-positive breast tumors and is postulated to be a major reason why many ER-positive breast cancer patients fail to respond when the antiestrogen tamoxifen is given as first-line therapy for recurrent disease. The objective of our project is to identify and characterize the post-translational molecular mechanism(s) accounting for the observed defect in ER-DNA binding function, enabling the design of future therapeutic modalities to reverse or prevent this ER defect and thereby restore endocrine sensitivity.

View original record on NIH RePORTER →